A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have limited use as first-line treatment for mutated EGFR metastatic non-small cell lung cancer. The French National Cancer Institute has installed molecular genetics platforms implementing EGFR and KRAS testing. However, there is co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of molecular diagnostics : JMD 2014-01, Vol.16 (1), p.45-55
Hauptverfasser: Beau-Faller, Michèle, Blons, Hélène, Domerg, Caroline, Gajda, Dorota, Richard, Nicolas, Escande, Fabienne, Solassol, Jérôme, Denis, Marc G, Cayre, Anne, Nanni-Metellus, Isabelle, Olschwang, Sylviane, Lizard, Sarab, Piard, Fabienne, Pretet, Jean-Luc, de Fraipont, Florence, Bièche, Ivan, de Cremoux, Patricia, Rouquette, Isabelle, Bringuier, Pierre-Paul, Mosser, Jean, Legrain, Michèle, Voegeli, Anne-Claire, Saulnier, Patrick, Morin, Franck, Pignon, Jean-Pierre, Zalcman, Gérard, Cadranel, Jacques
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!